학술논문
1185MO Activity and safety of avelumab alone or in combination with cabozantinib in patients with advanced high grade neuroendocrine neoplasias (NEN G3) progressing after chemotherapy. The phase II, open-label, multicenter AVENEC and CABOAVENEC trials
Document Type
Abstract
Author
Source
In Annals of Oncology October 2023 34 Supplement 2:S702-S702
Subject
Language
ISSN
0923-7534